GRCE — Grace Therapeutics, Share Price
Last trade - 00:00- $30.77m
- $19.72m
- 19
- 55
- 86
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.59 | ||
| Price to Tang. Book | 10.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.29% | ||
| Return on Equity | -22.89% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.2 | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Directors
- Roderick Carter CHM
- Janelle D'Alvise PRE
- Brian Ford CFO (72)
- Pierre Lemieux COO
- Brian Groch OTH
- Jean-Marie Canan IND (65)
- Donald Olds IND (61)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 7th, 2024
- Public Since
- March 7th, 2013
- No. of Employees
- 32
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,139,861
- Address
- 103 Carnegie Center, Suite 300, PRINCETON, 08540
- Web
- https://www.gracetx.com/
- Phone
- +1 6093221602
- Auditors
- Ernst & Young LLP
Upcoming Events for GRCE
Similar to GRCE
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 20:55 UTC, shares in Grace Therapeutics, are trading at $3.04. This share price information is delayed by 15 minutes.
Shares in Grace Therapeutics, last closed at $3.04 and the price had moved by +0.17% over the past 365 days. In terms of relative price strength the Grace Therapeutics, share price has underperformed the S&P500 Index by -9.68% over the past year.
The overall consensus recommendation for Grace Therapeutics, is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreGrace Therapeutics, does not currently pay a dividend.
Grace Therapeutics, does not currently pay a dividend.
Grace Therapeutics, does not currently pay a dividend.
To buy shares in Grace Therapeutics, you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.04, shares in Grace Therapeutics, had a market capitalisation of $30.77m.
Here are the trading details for Grace Therapeutics,:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GRCE
Based on an overall assessment of its quality, value and momentum Grace Therapeutics, is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Grace Therapeutics, is $11.91. That is 292.42% above the last closing price of $3.04.
Analysts covering Grace Therapeutics, currently have a consensus Earnings Per Share (EPS) forecast of -$1.24 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Grace Therapeutics,. Over the past six months, its share price has underperformed the S&P500 Index by -1.65%.
As of the last closing price of $3.04, shares in Grace Therapeutics, were trading +1.45% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Grace Therapeutics, PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Grace Therapeutics,'s management team is headed by:
- Roderick Carter - CHM
- Janelle D'Alvise - PRE
- Brian Ford - CFO
- Pierre Lemieux - COO
- Brian Groch - OTH
- Jean-Marie Canan - IND
- Donald Olds - IND